Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 701–800 of 1,003
Herald, J., Goitia, J. J., Duan, L., Chen, A., & Lee, M. S. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00533-w · Cited by 20
Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome
Meerhaeghe, T. V., Cez, A., Dahan, K., Estève, E., Elalamy, I., Boffa, J. J., & Ponlot, E. (2022) · TH Open · doi:10.1055/a-1920-6224 · Cited by 20
Божкова, С. А., Муртузалиевич, Т. Р., Andriyashkin, V. V., Akhtyamov, I. F., Belov, M. V., Dianov, S. V., Kasimova, A. R., Анатольевич, К. О., Kopenkin, S. S., Malanin, D. A., et al. (2022) · Traumatology and Orthopedics of Russia · doi:10.17816/2311-2905-1993 · Cited by 24
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art
Monaco, G., Bucherini, L., Stefanini, B., Piscaglia, F., Foschi, F. G., & Ielasi, L. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4962 · Cited by 21
Frank, B., Ariza, L., Lamparter, H., Grossmann, V., Prochaska, J. H., Ullmann, A., Kindler, F., Weißer, G., Walter, U., Lackner, K. J., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008157 · Cited by 22
Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants
Summers, R. L., & Sterling, S. A. (2016) · Air Medical Journal · doi:10.1016/j.amj.2016.01.001 · Cited by 22
Specific antidotes for bleeding associated with direct oral anticoagulants
Burnett, A., Siegal, D. M., & Crowther, M. A. (2017) · BMJ · doi:10.1136/bmj.j2216 · Cited by 20
Steuber, T. D., Shiltz, D. L., Cairns, A. C., Ding, Q., Binger, K. J., & Courtney, J. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717282 · Cited by 20
Asad, Z. U. A., Ijaz, S. H., Chaudhary, A. M. D., Khan, S. U., & Pakala, A. V. (2019) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2019.04.002 · Cited by 24
“Randomized controlled trials have compared the safety and efficacy of Apixaban to warfarin, and it was subsequently approved by FDA for treatment of deep venous thrombosis (DVT), pulmonary embolism (PE) and for prevention of stroke and thromboembolism in patients with non-valvular atrial fibrillation (AF) [1,2].”
BackgroundPatel, A., Williams, H., Baer, M. R., Zimrin, A. B., & Law, J. Y. (2019) · Acta Haematologica · doi:10.1159/000500223 · Cited by 20
Assessing patient preferences for switching from warfarin to direct oral anticoagulants
Wright, J. N., Vazquez, S. R., Kim, K., Jones, A. E., & Witt, D. M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01915-9 · Cited by 20
Dawwas, G. K., Smith, S. M., Dietrich, E. A., Lo‐Ciganic, W., & Park, H. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz307 · Cited by 20
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism
Koehl, J. L., Hayes, B. D., Al-Samkari, H. T., & Rosovsky, R. P. G. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1711731 · Cited by 21
“5 mg twice daily and by 76% with apixaban 5 mg twice daily as compared with placebo [11].”
BackgroundMethodKim, J. H., Seo, S., Kim, K., Chang, H.-M., Ryoo, B., Yoo, C., Jeong, J. H., Lee, J. L., Im, H.-S., Jeong, H., et al. (2020) · In Vivo · doi:10.21873/invivo.11845 · Cited by 20
Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms
Falanga, A., Marchetti, M., & Schieppati, F. (2021) · Hämostaseologie · doi:10.1055/a-1334-3259 · Cited by 26
The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE
Goto, S., Turpie, A. G. G., Farjat, A. E., Weitz, J. I., Haas, S. K., Ageno, W., Goldhaber, S. Z., Angchaisuksiri, P., Kayani, G., MacCallum, P., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.007 · Cited by 25
Self-citationSaddle Pulmonary Embolism: Demographics, Clinical Presentation, and Outcomes
Wong, K., Kushnir, M., & Billett, H. H. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000437 · Cited by 20
Bauersachs, R. M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.05.017 · Cited by 20
“The role of theNOACs in treating acute DVT, acute PE and preventing recurrence has been investigated in several randomised, controlled, phase III non-inferiority studies (Table 2) [20,21,48–51].”
BackgroundResultInfluentialDirect oral anticoagulants: unique properties and practical approaches to management
Barnes, G. D., & Kurtz, B. (2016) · Heart · doi:10.1136/heartjnl-2015-309075 · Cited by 22
Quick reference guide to apixaban
Hurst, K. V., O'Callaghan, J. M., & Handa, A. I. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121944 · Cited by 22
“routine monitoring (Table 2).(4) Currently available preparations include Eliquis (Bristol-Myers Squibb Pharmaceuticals Ltd).”
Jonsson, P. I., Letertre, L., Júlíusson, S., Guðmundsdóttir, B. R., Francis, C. W., & Onundarson, P. T. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13549 · Cited by 19
Sciascia, S., Radin, M., Schreiber, K. I., Fenoglio, R., Baldovino, S., & Roccatello, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1753-2 · Cited by 22
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
Frost, C. E., Ly, V. T., & Merali, S. J. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00359-y · Cited by 20
Crouch, A., Ng, T. H., Kelley, D., Knight, T., Edwin, S. B., ASCEND‐HIGHER, & Giuliano, C. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2655 · Cited by 19
Direct Oral Anticoagulants and Coronary Artery Disease
Choxi, R., Kapoor, K., Mackman, N., & Jovin, I. S. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317171 · Cited by 21
Papazoglou, Α. S., Moysidis, D. V., Κάρτας, Α., Bekiaridou, Α., Samaras, A., & Giannakoulas, G. A. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16508 · Cited by 23
Talerico, R., Pola, R., Klok, F. A., & Huisman, M. V. (2024) · TH Open · doi:10.1055/s-0043-1776989 · Cited by 20
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs)
Werth, S., Breslin, T., NíAinle, F., & Beyer‐Westendorf, J. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0123-6 · Cited by 20
Prandoni, P. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.013 · Cited by 21
“001) [26].”
BackgroundInferior vena cava filters: current best practices
Rajasekhar, A. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1187-5 · Cited by 19
“This conclusion may change with the emergence of newer oral anticoagulants that appear at least as effective as warfarin in the treatment of VTE with potentially less bleeding [57–61].”
BackgroundDirect oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
Fontana, P., Goldhaber, S. Z., & Bounameaux, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu027 · Cited by 22
“) was compared with conventional anticoagulant treatment in AMPLIFY.(14) Patients were included if they had symptomatic DVT and/or PE, and apixaban could be given upfront without initial administration of LMWH.”
Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism
Bacchus, F., & Schulman, S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303396 · Cited by 23
Efficacy and safety of direct oral anticoagulants after pulmonary embolism: A meta-analysis
Vedovati, M. C., Becattini, C., Germini, F., & Agnelli, G. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.136 · Cited by 20
“Rivaroxaban and apixaban were used following the single-drug approach (heparin not given or given for no longer than 48 h) [3,6].”
MethodSelf-citationTripodi, A., Padovan, L., Testa, S., Legnani, C., Chantarangkul, V., Scalambrino, E., Ludovici, S., Bassi, L., & Peyvandi, F. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0531 · Cited by 19
Anticoagulation Therapy and NOACs in Heart Failure
Thomas, I. C., EncisoSilva, J., Schlueter, M., & Greenberg, B. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_126 · Cited by 19
Signorelli, J., & Gandhi, A. S. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217739683 · Cited by 19
Zhao, Y., Ding, A., Arya, R., & Patel, J. P. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0734-5 · Cited by 20
Merali, S. J., Byon, W., Myers, E., Li, X., Marchisin, D., & Murthy, B. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00348-2 · Cited by 20
“Apixaban is an oral, selective, direct-reversible inhibitor of coagulation factor Xa that is approved in a number of countries for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery [1–3], for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial…”
BackgroundInfluentialYamashita, Y., Murata, K., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.10.029 · Cited by 20
Saleiro, C., Lopes, J., Campos, D. D., Puga, L., Costa, M. A. D. S., Gonçalves, L. M. M., & Teixeira, R. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420977567 · Cited by 19
“VKA (n 1⁄4 62) 62 + 14 55 (89) 18 (29) 9 (15) 19 (31) N.”
Chen, J., Lv, M., Wu, S., Jiang, S., Xu, W., Qian, J., Chen, M., Fang, Z., Zeng, Z., & Zhang, J. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.054 · Cited by 21
Fanikos, J. R., Goldstein, J. N., Lovelace, B., Beaubrun, A. C., Blissett, R. S., & Aragão, F. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2042106 · Cited by 19
Kobayashi, R., Cetatoiu, M. A., Esteso, P., Ventresco, C., Hawkins, B., Daly, K. P., Blume, E. D., Fynn‐Thompson, F., & VanderPluym, C. J. (2023) · ASAIO Journal · doi:10.1097/mat.0000000000001889 · Cited by 21
Li, M., Li, J., Wang, X., Xu, H., Wang, Q., Xie, S., Yan, P., Tian, J., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub3 · Cited by 26
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Pharmacologic Therapies in Anticoagulation
Ferreira, J. L., & Wipf, J. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.007 · Cited by 20
Rollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists
Brekelmans, M. P. A., Bleker, S. M., Bauersachs, R. M., Boda, Z., Buller, H. R., Choi, Y., Gallus, A. S., GROSSO, M. A., Middeldorp, S., Oh, D., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-11-0892 · Cited by 19
Self-citationRivera‐Caravaca, J. M., Harrison, S. L., Buckley, B. J. R., Fazio‐Eynullayeva, E., Underhill, P., Marín, F. R., & Lip, G. Y. H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01368-6 · Cited by 18
Williams, M. A., Ahuja, T., Raco, V., Papadopoulos, J., Green, D., Yuriditsky, E., & Arnouk, S. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02641-5 · Cited by 18
“[6, 7, 10] The two recurrent thromboembolic events in the reduced leadin group were in patients with active cancer, a known risk factor for recurrent VTE, despite adequate anticoagulation.”
BackgroundResultInfluentialLi, A., Zhang, M. C., Li, P., Eshaghpour, A., Li, K. T., Carrier, M., Wells, P. S., & Crowther, M. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.003 · Cited by 18
Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 27
“O acompanhamento laboratorial da sua atividade não se faz necessária 92,93 .”
BackgroundWeekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
Laliberté, F., Coleman, C. I., Bookhart, B., Lefèbvre, P., Cloutier, M., Damaraju, C. V., Schein, J. R., & Kaatz, S. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915801 · Cited by 20
Verso, M., Agnelli, G., & Prandoni, P. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1233-5 · Cited by 19
“term treatment of VTE showed non-inferior efficacy with a potentially better safety profile for the new oral anticoagulants (NOACs) in comparison to the conventional anticoagulation [18–24].”
BackgroundSelf-citationUresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Riess, H. B., Habbel, P., Jühling, A., Sinn, M., & Pelzer, U. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i3.258 · Cited by 19
The creation and implementation of an outpatient pulmonary embolism treatment protocol
Kabrhel, C., Rosovsky, R. P. G., Baugh, C. W., Parry, B. A., Deadmon, E. K., Kreger, C., & Giordano, N. J. (2017) · Hospital Practice · doi:10.1080/21548331.2017.1318651 · Cited by 18
“approved for PE treatment in patients with renal failure, though data are relatively sparse in this population and caution is recommended, so our protocol recommends admission for monitoring for all patients with CrCl <30 [32].”
MethodCancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
Smrke, A., & Gross, P. L. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00142 · Cited by 21
“S had metastatic melanoma and a DVT which was initially treated with LMWH and then switched to a DOAC when his disease was stable.”
BackgroundInfluentialBrandão, G. M. S., Cândido, R. C. F., Rollo, H. A., Sobreira, M. L., & Junqueira, D. R. (2018) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.005518 · Cited by 33
Sakamoto, Y., Nito, C., Nishiyama, Y., Suda, S., Matsumoto, N., Aoki, J., Shimoyama, T., Kanamaru, T., Suzuki, K., Nishimura, T., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0938 · Cited by 19
Cohen, A. T., Agnelli, G., Buller, H. R., Gallus, A. S., Raskob, G. E., Sanders, P. W., Thompson, J. R., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676983 · Cited by 18
Self-citationWoller, S. C., Stevens, S. M., Johnson, S. A., Bledsoe, J. R., Galovic, B., Lloyd, J. F., Wilson, E. L., Armbruster, B. P., & Evans, R. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12208 · Cited by 21
Nakamura, M., Yamada, N., Asamura, T., Shiosakai, K., & Uchino, K. (2020) · Circulation Reports · doi:10.1253/circrep.cr-19-0127 · Cited by 21
“4 – 7 , 15 – 17 Given that most patients with high bleeding risk receive the low dose (30 mg) of edoxaban according to the PI, information regarding the safety and effectiveness of edoxaban in such patients is of particular importance.”
Frère, C., Crichi, B., Lejeune, M., Spano, J., & Janus, N. (2020) · Cancers · doi:10.3390/cancers12040917 · Cited by 22
Leven, C., Hoffmann, C., Roche, C., Couturaud, F., Thereaux, J., & Lacut, K. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12587 · Cited by 19
Lachant, D. J., Bach, C., Fe, A., White, R. J., & Lachant, N. A. (2020) · ERJ Open Research · doi:10.1183/23120541.00554-2020 · Cited by 19
Lüscher, T. F., Davies, A. J., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 21
Kabrhel, C., Vinson, D. R., Mitchell, A. M., Rosovsky, R. P. G., Chang, A. M., Hernandez‐Nino, J., & Wolf, S. J. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12588 · Cited by 19
Wysokiński, W. E., Houghton, D. E., Vlazny, D. T., Ashrani, A. A., Froehling, D. A., Kamath, P. S., Meverden, R. A., Hodge, D. O., Peterson, L. G., Lang, T. R., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.005 · Cited by 18
Senoo, K., Kondo, Y., Miyazawa, K., Isogai, T., Chun, Y., & Kobayashi, Y. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.07.007 · Cited by 19
Gao, S., Wei, W., Chen, J.-T., Tan, Y.-H., Yu, C.-B., Litzow, M. R., & Liu, Q.-J. (2016) · Medicine · doi:10.1097/md.0000000000004658 · Cited by 23
Hernandez, C. M. R., Oo, T. H., & García‐Perdomo, H. A. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1434-4 · Cited by 18
Direct oral anticoagulants in the treatment of pulmonary embolism
Eldredge, J. B., & Spyropoulos, A. C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1364227 · Cited by 21
“Evidence related to treatment of cancerrelated PE with DOACs is limited, although 3% to 9% of patients included in the phase 3 VTE treatment trials of the 4 DOACs had active cancer or a history of cancer [22, 23, 25, 29, 32].”
BackgroundInfluentialRoberts, M. Z., Gaskill, G. E., Kanter-Washko, J., Kyle, T. R., Jones, B. C., & Bohm, N. M. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1637-y · Cited by 49
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants
Vedovati, M. C., Giustozzi, M., & Becattini, C. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.031 · Cited by 18
Lung Disease in Antiphospholipid Syndrome
Maioli, G., Calabrese, G., CAPSONI, F., Gerosa, M., Meroni, P. L., & Chighizola, C. B. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1683994 · Cited by 22
Shah, R., Sheikh, N., Mangwani, J., Morgan, N. J., & Khairandish, H. (2020) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2020.08.005 · Cited by 19
Shrestha, D. B., Budhathoki, P., Adhikari, A., Shrestha, S., Khati, N., Mir, W. A. Y., Joshi, T., & Shrestha, A. (2021) · Cureus · doi:10.7759/cureus.20632 · Cited by 17
“As a result, the indications of DOAC have significantly expanded in the last decade [1-5].”
BackgroundSu, X., Yan, B., Wang, L., Cheng, H., & Chen, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048619 · Cited by 17
Spénard, E., Geerts, W. H., Lin, Y., Gien, L. T., Kupets, R., Covens, A., & Vicus, D. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.02.012 · Cited by 18
Platelet and HIV Interactions and Their Contribution to Non-AIDS Comorbidities
Awamura, T., Nakasone, E. S., Gangcuangco, L. M. A., Subia, N., Bali, A.-J., Chow, D. C., Shikuma, C. M., & Park, J. (2023) · Biomolecules · doi:10.3390/biom13111608 · Cited by 18
Lawal, O. D., Aronow, H. D., Hume, A. L., Shobayo, F. O., Matson, K. L., Barbour, M. M., Zhang, Y., & Wen, X. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102293 · Cited by 19
“We chose a primary follow-up time of up to 183 days for outcome assessment to align with the pivotal trials for VTE [12 – 15] and because the recommended treatment duration for primary treatment of acute VTE is 3 to 6 months [7].”
BackgroundMethodResultInfluentialExpanding use of new oral anticoagulants
Weitz, J. I. (2014) · F1000Prime Reports · doi:10.12703/p6-93 · Cited by 18
Self-citationRoberts, K. M., Knight, T., Padilla‐Tolentino, E., Murthy, M. S., & Peterson, E. J. (2015) · Thrombosis · doi:10.1155/2015/414523 · Cited by 17
Bleeding complications in venous thrombosis patients on well-managed warfarin
Sandén, P., Renlund, H., Svensson, P. J., & Själander, A. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1305-4 · Cited by 17
“7 to 61 % [9–11].”
BackgroundInfluentialCohen, A. T., Buller, H. R., Agnelli, G., Gallus, A. S., Raskob, G. E., Weitz, J. I., Curto, M., Sisson, M., Middeldorp, S., & Bleker, S. M. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0137 · Cited by 17
“32 (15) 35 (16) 24 (11) 38 (18) 4 (2) 62 (29) 20 (9) 28 (10 – 82)”
BackgroundMethodSelf-citationBetrixaban – the next direct factor Xa inhibitor?
Thoenes, M., Minguet, J., Bramlage, K., Bramlage, P., & Ferrero, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1256194 · Cited by 19
“terms of efficacy and safety and as rapid as heparin in terms of onset of action [16, 17].”
BackgroundAppropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment
Tran, E., Duckett, A. A., Fisher, S., & Bohm, N. M. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1487-z · Cited by 18
Badreldin, H. A. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1661-y · Cited by 18
Ikeda, S., Koga, S., Yamagata, Y., Eguchi, M., Sato, D., Muroya, T., Yonekura, T., Tsuneto, A., Yoshimuta, T., Koide, Y., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.03.006 · Cited by 18
Jobski, K., Hoffmann, F., Herget‐Rosenthal, S., & Dörks, M. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01526-7 · Cited by 17
Farge, D., Maignan, C. L., Doucet, L. S., & Frère, C. (2019) · Thrombosis Research · doi:10.1016/s0049-3848(19)30367-6 · Cited by 20
Tchen, S., Ryba, N., Patel, V. V., Cavanaugh, J., & Sullivan, J. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020933186 · Cited by 19
Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism
Trujillo‐Santos, J., Beroiz, P., Moustafa, F., Álvarez, A. A., Morejon, E., López-Reyes, R., Casado, I., Porras, J. A., Flores, K., López-Núñez, J. J., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.035 · Cited by 18
Frost, C. E., Merali, S. J., Shenker, A., Barrett, Y. C., & LaCreta, F. P. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.990 · Cited by 19
Bleeding complications of targeted oral anticoagulants: what is the risk?
Levine, M., & Goldstein, J. N. (2014) · Hematology · doi:10.1182/asheducation-2014.1.504 · Cited by 20
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.002 · Cited by 25
Self-citationGallus, A. S., Sanders, P. W., Thompson, J. R., Agnelli, G., Buller, H. R., Cohen, A. T., Ramacciotti, E., Weitz, J. I., & Raskob, G. E. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-09-0752 · Cited by 18
“Apixaban was non-inferior to conventional therapy and was associated with a significant reduction in major and/or clinically relevant non-major bleeding (3).”
BackgroundMethodResultSelf-citationAnticoagulant therapy after venous thromboembolism and 10-year mortality
Larsen, T. B., Lip, G. Y. H., & Gorst‐Rasmussen, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.190 · Cited by 17
Cancer-Associated Venous Thromboembolism
Elewa, H. F., Elrefai, R., & Barnes, G. D. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0445-y · Cited by 17
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.